Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
183 hedge funds and large institutions have $214M invested in Esperion Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 22 closing their positions.
41% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $2.19M
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
4% more funds holding
Funds holding: 176 → 183 (+7)
6.31% less ownership
Funds ownership: 72.33% → 66.02% (-6.3%)
30% less capital invested
Capital invested by funds: $304M → $214M (-$89.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$13.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.5M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$3.12M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.16M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.9M |
| 2 |
Millennium Management
New York
|
-$6.28M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.66M |
| 4 |
WCM
Whitefort Capital Management
New York
|
-$5.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.8M |
ESPR Hedge Fund Activity: Q3 2024 in Review
183 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2024, worth a combined $214M — down 30% from $304M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ESPR positions and 22 closed out — a net gain of 8 holders — while 50 added to existing stakes and 44 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $13.1M. The largest seller was Great Point Partners, exiting entirely with an estimated $12.9M sold.
- 183 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2024, up from 176 in Q2 2024.
- Funds reported $214M of Esperion Therapeutics stock for Q3 2024, down 30% quarter-over-quarter.
- 30 funds opened new Esperion Therapeutics positions in Q3 2024 and 22 closed out, a net change of +8 holders.
- The largest Esperion Therapeutics buyer in Q3 2024 was Wasatch Advisors, an estimated $13.1M added.
- The largest Esperion Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2024.